ImmunoPrecise Begins Path to NASDAQ

This morning ImmunoPrecise Antibodies Ltd (TSXV: IPA) announced they have commenced the application process to dual list their stock on the NASDAQ. In the news release, the company states they believe the move will gain greater exposure for the company to access a larger base of retail and institutional investors in the United States and internationally.

ImmunoPrecise Antibodies Ltd. Logo (CNW Group/ImmunoPrecise Antibodies Ltd.)

ImmunoPrecise is a full-service, therapeutic antibody discovery company utilizing species agnostic, multi-format, characterized and engineered, human monoclonal antibodies, on an abbreviated timeframe. IPA has developed a technology platform with end-to-end solutions empowering companies to discover and develop therapies against any disease. Their full-service capabilities reduce the time and risk associated with conventional multi-vendor product development.

The company has been working on COVID by identifying antibodies derived from multiple species (human, llama, Ligand’s humanized OmniRat, and wild-type rabbits) which demonstrate potent, in vitro neutralizing activity. They have discovered their functional antibodies using the Company’s DeepDisplay phage technology, B Cell Select and Single Step Hybridoma platforms.

At the time of publishing IPA stock is trading at $1.85 an increase of 3.9%.

PTX Metals Inc. — sponsored Sponsored · PTX Metals Inc.

Information for this analysis was found via Sedar and ImmunoPrecise Antibodies Ltd. The author is long common shares of ImmunoPrecise Antibodies (IPA.v). Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Inside a Forgotten High-Grade Gold Mine in the Yukon | Blue Jay Gold [DD-on-the-GO Ep. 10]

WHICH MINING STOCKS CAN STILL RUN? | Mining Stock Mailbag [Nov. 9-13]

Silver’s Bull Market Isn’t Over | Peter Krauth

Recommended

Epic Gold Delivers Maiden 279,000 Ounce Inferred Resource at Wilson Project

First Phosphate Adds UK Export Finance to Growing Export Credit Lineup With C$220 Million Letter of Interest

Related News

Revive Therapeutics Partners With UCSF To Study Bucillamine For Severe COVID-19

Revive Therapeutics (CSE: RVV) this morning had a major announcement, in that it has entered...

Monday, May 3, 2021, 09:24:15 AM

Mask Mandates Return as Rate of Hospitalization Increases in the US

Morris Brown College, a private Atlanta institution, has reissued a face mask mandate for its...

Wednesday, August 23, 2023, 02:09:00 PM

ImmunoPrecise Repays $2.75 Million In Debt, Sees $3.8 Million In Warrants Exercised

ImmunoPrecise Antibodies (TSXV: IPA) announced this morning that it has managed to remove outstanding convertible...

Monday, July 20, 2020, 09:21:38 AM

Bank Of Canada Pandemic Purchases Total To $795 Billion–Report

The COVID-19 pandemic triggered a global economic crisis, sending shockwaves through financial markets. In a...

Friday, October 13, 2023, 10:29:00 AM

Pentagon’s Secret Anti-Vax Campaign to Undermine China During Pandemic Exposed

An extensive investigation by Reuters has unveiled a clandestine campaign by the U.S. military aimed...

Sunday, June 16, 2024, 11:45:00 AM